Vivas Marcelo Dayrell, Correia Tiago, Bragagnolo Larissa, da Silva Igor Antônio Lourenço, Tureck Fernando, Santos Reinaldo, Kielmann Samara, do Carmo Debora, Avarca Camila, da Silva Franciele, Paes Mariana, Tofani Luis Fernando Nogueira, Chioro Arthur
Laboratório de Saúde Coletiva, LASCOL, Departamento de Medicina Preventiva, Escola Paulista de Medicina, EPM, Universidade Federal de São Paulo, Sao Paulo, São Paulo, Brazil.
Global Health and Tropical Medicine - Associate Laboratory in Translation and Innovation Towards Global Health, Universidade Nova de Lisboa Instituto de Higiene e Medicina Tropical, Lisboa, Portugal
BMJ Open. 2025 Jul 17;15(7):e096904. doi: 10.1136/bmjopen-2024-096904.
The COVID-19 pandemic's unprecedented nature has exposed significant vulnerabilities in most public health systems and highlighted the importance of coordinated responses across various levels of government. A global debate emerged on the types of health measures necessary to curb the rapid spread of contagious and/or lethal diseases. However, some of these measures involved restricting individual rights, raising significant ethical, legal and public health questions. The protocol of this systematic review aims to address a critical gap in the literature by analysing how Public Health Surveillance services worldwide implemented compulsory right-restricting measures during the COVID-19 pandemic, and what impacts these measures had on public health outcomes and individual rights.
This protocol focuses on studies about right-restricting measures enacted by Public Health Surveillance services during the COVID-19 pandemic. It will be unrestrictive as to period (starting in 2019, when the outbreak was identified), language or publication status in a preliminary stage. It will include only peer-reviewed publications, discarding opinion articles, editorials, conference papers and non-peer-reviewed publications. Considering the PICo strategy, the research question of this systematic review can be formulated as follows: Problem-right-restricting measures enacted by Public Health Surveillance services; Interest-implementation modalities and impacts on individual rights and public health outcomes; Context-COVID-19 pandemic. This protocol will use the following databases: Pubmed, Cochrane/CENTRAL, Embase, Scopus and Web of Science. Considering the various measures that may have been adopted, the following categories of analysis will be used: (i) Public Health Surveillance as a field, (ii) the various specific areas of Health Surveillance, (iii) law enforcement, (iv) right-restricting measures and consent, (v) interactions between right-restricting measures and routine Public Health Surveillance functions, (vi) differences between countries and (vii) Health Surveillance lessons learnt from the COVID-19 pandemic. These categories are not strictly mutually exclusive; however, each study will be assigned to the category most aligned with its primary focus. To ensure the validity and reliability of findings, each study will have its risk of bias assessed at both the study and outcome levels.
Patients and the public were not involved in the design, conduct, reporting or dissemination plans of this systematic review. The results will be presented in one or more articles to be submitted to scientific journals and may also be presented at scientific conferences and to public policy makers.
This systematic review protocol was registered with the International Prospective Register of Systematic Reviews (PROSPERO) on 20 November 2024 (registration number CRD42024613039).
新冠疫情的特殊性暴露了大多数公共卫生系统的重大脆弱性,并凸显了各级政府协调应对的重要性。关于遏制传染性和/或致命疾病快速传播所需的卫生措施类型展开了全球辩论。然而,其中一些措施涉及限制个人权利,引发了重大的伦理、法律和公共卫生问题。本系统评价方案旨在通过分析全球公共卫生监测服务在新冠疫情期间如何实施强制性权利限制措施,以及这些措施对公共卫生结果和个人权利产生了何种影响,来填补文献中的关键空白。
本方案聚焦于关于公共卫生监测服务在新冠疫情期间颁布的权利限制措施的研究。在初步阶段,对研究时期(从2019年疫情被发现开始)、语言或发表状态不设限制。仅纳入同行评审出版物,排除观点文章、社论、会议论文和非同行评审出版物。考虑PICo策略,本系统评价的研究问题可表述如下:问题——公共卫生监测服务颁布的权利限制措施;兴趣点——实施方式及其对个人权利和公共卫生结果的影响;背景——新冠疫情。本方案将使用以下数据库:PubMed、Cochrane/CENTRAL、Embase、Scopus和Web of Science。考虑到可能采取的各种措施,将采用以下几类分析:(i)作为一个领域的公共卫生监测;(ii)卫生监测的各个具体领域;(iii)执法;(iv)权利限制措施与同意;(v)权利限制措施与常规公共卫生监测职能之间的相互作用;(vi)国家间差异;(vii)从新冠疫情中吸取的卫生监测经验教训。这些类别并非严格相互排斥;然而,每项研究将被归入与其主要重点最相符的类别。为确保研究结果的有效性和可靠性,将在研究和结果层面评估每项研究的偏倚风险。
患者和公众未参与本系统评价的设计、实施、报告或传播计划。研究结果将在一篇或多篇提交给科学期刊的文章中呈现,也可能在科学会议上向公共政策制定者展示。
PROSPERO注册号:本系统评价方案于2024年11月20日在国际系统评价前瞻性注册库(PROSPERO)注册(注册号CRD42024613039)。